Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease

We present a case of refractory ileocolonic Crohn's disease in a 27-year-old female treated with dual ustekinumab and vedolizumab biologic therapy. She had mucosal healing for the first time in 13 years after a 10-month treatment of ustekinumab overlapped with 6 months of vedolizumab. No side e...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Eddie Y., Loomes, Dustin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698793/
https://www.ncbi.nlm.nih.gov/pubmed/29250117
http://dx.doi.org/10.1155/2017/5264216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698793/
https://www.ncbi.nlm.nih.gov/pubmed/29250117
http://dx.doi.org/10.1155/2017/5264216

Ejemplares similares